On April 25th, according to a report by "Economic Observer Net", RELX Yueke has applied for nearly 900 patents worldwide, and has ranked first among domestic electronic cigarette brands in patent applications for five consecutive years.
The patent layout of YUEKE covers multiple areas including electronic atomizer design, vapor liquid formulation, release substance safety, and intelligence.
According to reports, since its establishment, Yueke has invested more than 800 million yuan in research and development, and has worked with several scientific research institutions to further improve the complete technical path of product quality, flavor development, experience upgrade, and scientific exploration.
In addition, Yueke has also been selected as a new enterprise with specialized expertise in Guangdong province, and has been awarded the title of "Guangdong Provincial Engineering Technology Center for New Type of Intelligent Atomization Devices and Inhalation Formulations", making it a leading player in the domestic electronic cigarette industry.
Related Reading:
E-cigarette brand RELX launches its disposable e-cigarette line, RELX MagicGo, in the UK.
Yueke International is set to establish long-term development in Germany, partnering with over 2,000 retailers within the first year.
In the fourth quarter, the daily average sales of Yueke reached approximately 3.8 million yuan. The CEO expressed confidence in the long-term growth of the industry.
References:
1) Economic Observer
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
